4-(6,7-Dimethoxy-quinazolin-4-yl)-piperidine-1-carboxylic acid (4-dimethylamino-phenyl)-amide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(6,7-Dimethoxy-quinazolin-4-yl)-piperidine-1-carboxylic acid (4-dimethylamino-phenyl)-amide
• 英文别名: 4-(6,7-dimethoxyquinazolin-4-yl)-N-[4-(dimethylamino)phenyl]piperidine-1-carboxamide
• 化学式: C₂₄H₂₉N₅O₃
• 分子量: 435.526
• InChiKey: ASIQFVWHYXKINC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  79.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  6,7-二甲氧基-4-(4-哌啶基)喹唑啉 、 4-二甲氨基苯异氰酸酯 在 silica gel 、 methanol-dichloromethane 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以to yield 19 mg (44%) of pure 4-(6,7-Dimethoxy-quinazolin-4-yl)-piperidine-1-carboxylic acid (4-dimethylamino-phenyl)-amide的产率得到4-(6,7-Dimethoxy-quinazolin-4-yl)-piperidine-1-carboxylic acid (4-dimethylamino-phenyl)-amide
  参考文献：
  名称：

  ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS

  摘要：

  该发明涉及公式I的烷基喹啉和烷基喹唑啉化合物：其中R1、R2、R3、B、Z、G、Q和X如本文所定义，使用这些化合物作为蛋白酪氨酸激酶调节剂，特别是FLT3和/或c-kit和/或TrkB的抑制剂，使用这些化合物来减少或抑制细胞或受体中FLT3和/或c-kit和/或TrkB的激酶活性，以及使用这些化合物来预防或治疗细胞增殖性疾病和/或与FLT3和/或c-kit和/或TrkB相关的疾病。本发明还涉及包含本发明化合物的制药组合物和用于治疗癌症和其他细胞增殖性疾病的方法。

  公开号：

  US20060281772A1

文献信息

• ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS
  申请人：Baindur Nand

  公开号：US20060281772A1

  公开（公告）日：2006-12-14

  The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I: wherein R 1 , R 2 , R 3 , B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  该发明涉及Formula I的烷基喹啉和烷基喹噁啉化合物： 其中R1、R2、R3、B、Z、G、Q和X如本文所定义，所述化合物的用途为蛋白酪氨酸激酶调节剂，特别是FLT3和/或c-kit和/或TrkB的抑制剂，所述化合物的用途为在细胞或受试者中减少或抑制FLT3和/或c-kit和/或TrkB的激酶活性，以及所述化合物的用途为预防或治疗受试者的细胞增殖紊乱和/或与FLT3和/或c-kit和/或TrkB相关的紊乱。本发明还涉及包括本发明化合物的药物组合物，以及治疗癌症和其他细胞增殖紊乱等疾病的方法。
• Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
  申请人：Baumann Andrew Christian

  公开号：US20070004660A1

  公开（公告）日：2007-01-04

  The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from alkylquinoline and alkylquinazoline compounds of Formula I′: where R 1 , R 2 , R 3 , Z, G, Q and X are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

  本发明涉及一种抑制细胞或主体中FLT3酪氨酸激酶活性或表达或减少FLT3激酶活性或表达的方法，包括给予一种法尼酰转移酶抑制剂和一种从式I'的烷基喹啉和烷基喹唑啉化合物中选择的FLT3激酶抑制剂：其中R1、R2、R3、Z、G、Q和X如本文所定义。本发明包括治疗和预防方法，用于治疗或预防患有细胞增殖性疾病或与FLT3相关的疾病的患者。
• US8071768B2
  申请人：——

  公开号：US8071768B2

  公开（公告）日：2011-12-06
• Alkylquinoline and alkylquinazoline kinase modulators
  申请人：Janssen Pharmaceutica, N.V.

  公开号：US08071768B2

  公开（公告）日：2011-12-06

  The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I: wherein R1, R2, R3, B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  本发明涉及式I的烷基喹啉和烷基喹唑啉化合物：其中R1、R2、R3、B、Z、G、Q和X如本文所定义，以及使用这些化合物作为蛋白酪氨酸激酶调节剂，特别是FLT3和/或c-kit和/或TrkB的抑制剂，使用这些化合物来减少或抑制细胞或主体中FLT3和/或c-kit和/或TrkB的激酶活性，以及使用这些化合物预防或治疗主体中细胞增殖性疾病和/或与FLT3和/或c-kit和/或TrkB有关的疾病。本发明还涉及包含本发明化合物的药物组合物以及治疗癌症和其他细胞增殖性疾病的方法。